We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
(Approval lapsed) Cholestyramine for oral suspension, USP light powder 4g pouch (Ascend, USA)
Section 19A approved medicine
(Approval lapsed) Cholestyramine for oral suspension, USP light powder 4g pouch (Ascend, USA)
Section 19A approval holder
Pharmacor Pty Ltd ABN 58 121 020 835
Phone
1300 138 805
Approved until
Status
Expired
Medicines in short supply/unavailable
QUESTRAN LITE colestyramine 850mg/g powder sachet - ARTG 11971
Indication(s)
- Reduction of serum cholesterol levels and prevention of coronary heart disease. Cholestyramine is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low-density lipoproteins). Cholestyramine may be useful to lower elevated cholesterol that occurs in patients with combined hypercholesterolemia and hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern.
- Relief of pruritus associated with partial biliary obstruction. Patients with primary biliary cirrhosis may exhibit elevated serum cholesterol as part of their disease. When cholestyramine is used to treat the pruritus of partial biliary obstruction, it may lower serum cholesterol levels, produce no change, or cause rapid escape from a temporary lowering to pre-treatment levels or rebound.
Images
